{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:10:31Z","timestamp":1787987431802,"version":"build-2784847793"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2012,12,8]],"date-time":"2012-12-08T00:00:00Z","timestamp":1354924800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/2.5"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1007\/s10549-012-2341-9","type":"journal-article","created":{"date-parts":[[2012,12,7]],"date-time":"2012-12-07T06:14:46Z","timestamp":1354860886000},"page":"457-464","source":"Crossref","is-referenced-by-count":31,"title":["Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen"],"prefix":"10.1007","volume":"137","author":[{"given":"Denise A.","family":"Yardley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lowell","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Bosserman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansoor N.","family":"Salleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Waterhouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maura K.","family":"Hagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Richards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle L.","family":"DeSilvio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine M.","family":"Mahoney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasir","family":"Nagarwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,12,8]]},"reference":[{"key":"2341_CR1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","volume":"62","author":"R Siegel","year":"2012","unstructured":"Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62:10\u201329","journal-title":"CA Cancer J Clin"},{"key":"2341_CR2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","volume":"2","author":"Y Yarden","year":"2001","unstructured":"Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127\u2013137","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2341_CR3","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science 235:177\u2013182","journal-title":"Science"},{"key":"2341_CR4","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","volume":"244","author":"DJ Slamon","year":"1989","unstructured":"Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE et al (1989) Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer. Science 244:707\u2013712","journal-title":"Science"},{"key":"2341_CR5","doi-asserted-by":"crossref","first-page":"e1000279","DOI":"10.1371\/journal.pmed.1000279","volume":"7","author":"FM Blows","year":"2010","unstructured":"Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J et al (2010) Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med 7:e1000279","journal-title":"PLoS Med"},{"key":"2341_CR6","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3816\/CBC.2005.n.026","volume":"6","author":"RD Mass","year":"2005","unstructured":"Mass RD, Press MF, Anderson S, Cobleigh MA, Vogel CL, Dybdal N et al (2005) Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer 6:240\u2013246","journal-title":"Clin Breast Cancer"},{"key":"2341_CR7","doi-asserted-by":"crossref","first-page":"5658","DOI":"10.1200\/JCO.2006.07.0250","volume":"24","author":"Z Gabos","year":"2006","unstructured":"Gabos Z, Sinha R, Hanson J, Chauhan N, Hugh J, Mackey JR et al (2006) Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol 24:5658\u20135663","journal-title":"J Clin Oncol"},{"key":"2341_CR8","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/ijc.2910490504","volume":"49","author":"OP Kallioniemi","year":"1991","unstructured":"Kallioniemi OP, Holli K, Visakorpi T, Koivula T, Helin HH, Isola JJ (1991) Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 49:650\u2013655","journal-title":"Int J Cancer"},{"key":"2341_CR9","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"353","author":"MJ Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659\u20131672","journal-title":"N Engl J Med"},{"key":"2341_CR10","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","volume":"353","author":"EH Romond","year":"2005","unstructured":"Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673\u20131684","journal-title":"N Engl J Med"},{"key":"2341_CR11","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783\u2013792","journal-title":"N Engl J Med"},{"key":"2341_CR12","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1634\/theoncologist.11-4-318","volume":"11","author":"F Montemurro","year":"2006","unstructured":"Montemurro F, Donadio M, Clavarezza M, Redana S, Jacomuzzi ME, Valabrega G et al (2006) Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy. Oncologist 11:318\u2013324","journal-title":"Oncologist"},{"key":"2341_CR13","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","volume":"355","author":"CE Geyer","year":"2006","unstructured":"Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733\u20132743","journal-title":"N Engl J Med"},{"key":"2341_CR14","unstructured":"http:\/\/www.cancer.gov\/cancertopics\/druginfo\/fda-lapatinib . Accessed 2 Oct 2012"},{"key":"2341_CR15","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1634\/theoncologist.2009-0240","volume":"15","author":"LS Schwartzberg","year":"2010","unstructured":"Schwartzberg LS, Franco SX, Florance A, O\u2019Rourke L, Maltzman J, Johnston S (2010) Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer. Oncologist 15:122\u2013129","journal-title":"Oncologist"},{"key":"2341_CR16","doi-asserted-by":"crossref","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","volume":"23","author":"WJ Gradishar","year":"2005","unstructured":"Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P et al (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23:7794\u20137803","journal-title":"J Clin Oncol"},{"key":"2341_CR17","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1200\/JCO.2008.18.5397","volume":"27","author":"WJ Gradishar","year":"2009","unstructured":"Gradishar WJ, Krasnojon D, Cheporov S, Makhson AN, Manikhas GM, Clawson A et al (2009) Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 27:3611\u20133619","journal-title":"J Clin Oncol"},{"key":"2341_CR18","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.clbc.2012.05.001","volume":"12","author":"WJ Gradishar","year":"2012","unstructured":"Gradishar WJ, Krasnojon D, Cheporov S, Makhson AN, Manikhas GM, Clawson A et al (2012) Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final analysis of overall survival. Clin Breast Cancer 12:313\u2013321","journal-title":"Clin Breast Cancer"},{"key":"2341_CR19","unstructured":"http:\/\/www.cancer.gov\/cancertopics\/druginfo\/fda-nanoparticle-paclitaxel . Accessed 2 Oct 2012"},{"key":"2341_CR20","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1093\/jnci\/djn216","volume":"100","author":"B Gril","year":"2008","unstructured":"Gril B, Palmieri D, Bronder JL, Herring JM, Vega-Valle E, Feigenbaum L et al (2008) Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst 100:1092\u20131103","journal-title":"J Natl Cancer Inst"},{"key":"2341_CR21","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1200\/JCO.2000.18.11.2349","volume":"18","author":"BC Pestalozzi","year":"2000","unstructured":"Pestalozzi BC, Brignoli S (2000) Trastuzumab in CSF. J Clin Oncol 18:2349\u20132351","journal-title":"J Clin Oncol"},{"key":"2341_CR22","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/sj.onc.1207166","volume":"23","author":"W Xia","year":"2004","unstructured":"Xia W, Liu LH, Ho P, Spector NL (2004) Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR\/ErbB2 kinase inhibitor GW572016. Oncogene 23:646\u2013653","journal-title":"Oncogene"},{"key":"2341_CR23","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1200\/JCO.2011.35.6725","volume":"30","author":"KL Blackwell","year":"2012","unstructured":"Blackwell KL, Burstein HJ, Storniolo AM, Rugo HS, Sledge G, Aktan G et al (2012) Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 study. J Clin Oncol 30:2585\u20132592","journal-title":"J Clin Oncol"},{"issue":"205","key":"2341_CR24","first-page":"16","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(205):16","journal-title":"J Natl Cancer Inst"},{"key":"2341_CR25","unstructured":"Greenwood M (1926) The natural duration of cancer. In: Reports on public health and medical subjects. London, England: His Majesty's Stationery Office, pp 1\u201326"},{"key":"2341_CR26","unstructured":"Guan ZZ, Xu BH, DeSilvio M, Shen ZZ, Arponwirat W, Tong ZS et al (in press) Randomized trial of lapatinib vs placebo added to paclitaxel in the treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol"},{"key":"2341_CR27","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000318043","volume":"79","author":"A Jagiello-Gruszfeld","year":"2010","unstructured":"Jagiello-Gruszfeld A, Tjulandin S, Dobrovolskaya N, Manikhas A, Pienkowski T, DeSilvio M et al (2010) A single-arm phase II trial of first-line paclitaxel in combination with lapatinib in HER2-overexpressing metastatic breast cancer. Oncology 79:129\u2013135","journal-title":"Oncology"},{"key":"2341_CR28","doi-asserted-by":"crossref","unstructured":"Di Leo A, Gomez HL, Aziz Z, Zvirbule Z, Bines J, Arbushites MC, et al (2008) Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 26:5544\u20135552. Erratum in: J Clin Oncol 2009;27:1923","DOI":"10.1200\/JCO.2008.16.2578"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-012-2341-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-012-2341-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-012-2341-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,6]],"date-time":"2019-07-06T20:05:46Z","timestamp":1562443546000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-012-2341-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,8]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["2341"],"URL":"https:\/\/doi.org\/10.1007\/s10549-012-2341-9","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,8]]}}}